Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TargetBRCA

Financiado

To develop a new targeted therapy for the treatment of naive and PARP inhibitor-...

To develop a new targeted therapy for the treatment of naive and PARP inhibitor-resistant BRCA1/2-mutated tumors Breast and ovarian carcinomas are aggressive tumors with few treatment options and high recurrence rates. About half of these tumors shows defects in homologous recombination (HR) repair. Defect in HR (HRD) causes genomic instabil... ver más

31/01/2024

INSTITUT CURIE FON...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-31

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1 Objective:Objectives:

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSTITUT CURIE FONDATION

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2014-57680-R PROFUNDIZANDO EN EL MECANISMO DE ACCION DE LOS INHIBIDORES D... 97K€ Cerrado

CNS2023-145149 Cáncer 200K€ Cerrado

SAF2012-40011-C02-01 CONTROL POR PARP-1 DE LA AUTOPHAGIA TUMORAL: IMPLICACIONES E... 152K€ Cerrado

BRCA-RLT Impact of BRCA2 deficiency one the DNA damage response and I... 188K€ Cerrado

PID2020-112526RB-I00 ESTUDIO DE LAS FUNCIONES ESPECIFICAS DE PARP-1 Y DE PARP-2 E... 218K€ Cerrado

PID2020-117815RB-I00 EL PERFIL METABOLICO COMO UNA OPORTUNIDAD TERAPEUTICA EN EL... 218K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-07-18
Fecha Fin: 2024-01-31

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Breast and ovarian carcinomas are aggressive tumors with few treatment options and high recurrence rates. About half of these tumors shows defects in homologous recombination (HR) repair. Defect in HR (HRD) causes genomic instability and dependence on poly (ADP-ribose) polymerase (PARP)-mediated DNA repair. As a result, PARP inhibitors (PARPi) are now widely used for the treatment of these tumors. However, resistance to PARPi is emerging as the major obstacle to clinical effectiveness. Consequently, many patients run out of treatment options and succumb to the disease. This prompts the development of novel therapeutics. Beyond its well-known functions in regulating metabolic processes, we discovered that enzyme X maintains genomic stability in HRD cells. Enzyme X inhibition kills HRD cells without affecting HR-proficient cell survival pointing to a synthetic lethal interaction between enzyme X and HR genes. Moreover, we showed that enzyme X functions independently of PARP in the survival of HRD cells. As a result, enzyme X inhibition kills naive and PARPi-resistant HRD cells. Thus, targeting this enzyme has the potential to provide a new cure for HRD tumors. No inhibitors nor patents on enzyme X exist. HRD tumors being a major economic burden worldwide, developing enzyme X inhibitors has high innovation and financial reward potentials. By screening chemical libraries, we identified a top hit inhibitor of enzyme X. Our TargetBRCA project aims at improving potency and specificity of our molecule inhibitor and provides a proof-of-concept on its use as a cure for HRD tumors. TargetBRCA relies on complementary teams of crystallographers, chemists and specialists of HRD tumor biology and associates structure-aided drug design with the use of preclinical in vivo models. Our ultimate goal is to foster the development of a clinical-grade inhibitor to be used for the treatment of HRD tumors either by licensing and co-development partnerships, or by the creation of a start-up.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores